Developer docs
API playgroundTry for free, no card

Search company profiles

Clear Labs

Full company profile

uuid00006pw

Namestring
Clear Labs
Legal namestring
Clear Labs, Inc.
Websiteurl
clearlabs.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Clear Labs is a San Carlos, California-based biotechnology company founded in 2014 by Sasan Amini (PhD, Princeton) that builds fully automated next-generation sequencing (NGS) platforms integrating liquid handling, library preparation, sequencing, and bioinformatics into a single turnkey system. The company's technology combines short-read Illumina sequencing-by-synthesis and long-read Oxford Nanopore technologies, supported by what the company describes as the world's largest molecular food database. Its product portfolio is organized into three lines: Clear Safety for food safety pathogen testing (Listeria and Salmonella with AOAC and USDA NPIP certifications), Clear Ix for infectious disease research and microbial surveillance (including SARS-CoV-2 wastewater monitoring, Mycobacterium detection, and Deeplex Myc-TB), and Clear Dx for oncology research workflows including solid tumor sequencing, liquid biopsy, and fusion detection.

The company generates revenue through sale or lease of NGS instruments, recurring consumables (reagents and kits), service contracts, and technology licensing. Go-to-market is enterprise sales-led with distribution partnerships extending reach through Illumina and Oxford Nanopore channels. Target customers span four primary verticals: food manufacturers and processors, public health laboratories, clinical microbiology laboratories, and oncology research institutions. Notable accounts include Mayo Clinic, Cleveland Clinic, Tyson Foods, Aviagen, Labcorp, Nebraska and Florida public health laboratories, and alignment with CDC PulseNet reporting standards.

Clear Labs has raised approximately $155.5M across eight disclosed funding rounds from 2014 through January 2025, with institutional backing from Menlo Ventures, Khosla Ventures, GV, Counterpoint Global, T. Rowe Price, and strategic investment from Tyson Ventures. Regulatory milestones include FDA Emergency Use Authorization for SARS-CoV-2 (2020), AOAC certifications for both Salmonella (2018) and Listeria (2019), and USDA NPIP approval for poultry Salmonella testing (2021). The company employs 51-100 people and is actively expanding internationally into Europe and Latin America while broadening its oncology footprint through partnerships with Labcorp and Pillar Biosciences announced in November 2025.

Short descriptiontext

Clear Labs is a San Carlos-based biotechnology company that builds fully automated next-generation sequencing platforms for food safety testing, infectious disease surveillance, and oncology research, serving public health laboratories, food manufacturers, and clinical microbiology laboratories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Carlos, United States
HQ citystring
San Carlos
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
automated genomic sequencing, food safety testing, infectious disease diagnostics, oncology research platforms, pathogen detection
Industry4 codes
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLACAMAK
Lab Analytics, Utilization Management & Operational Intelligence
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Laboratory Apparatus & Furniture3821
Product category
Automated Genomics Sequencing Platforms
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1NGS Platform Sales and Service
TypeHardware Sales
Description

Clear Labs generates revenue through the sale and service of its automated NGS platforms including Clear Dx, Clear Ix, and Clear Safety systems. Revenue comes from instrument sales, consumables (reagents, kits), and service contracts for maintenance and support. The company offers both purchase and lease arrangements for its platforms.

clearlabs.com
2Testing Services and Consumables
TypeUsage Based
Description

Ongoing revenue from consumables used with the NGS platforms for pathogen detection, serotyping, and genomic surveillance applications. Customers include food safety labs, public health laboratories, and clinical microbiology labs that run routine tests.

clearlabs.com
3Technology Licensing and Partnerships
TypeLicensing Royalties
Description

Revenue derived from licensing technology to partners including Labcorp for oncology workflows and distribution agreements with Illumina and Oxford Nanopore for sequencing technology integration.

clearlabs.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise platform sale with flexible arrangements
ModelOtherBilling cadenceMulti-year contract
Notes

Clear Labs offers both purchase and lease arrangements for its Clear Dx, Clear Ix, and Clear Safety platforms. Specific pricing is not publicly disclosed and requires direct inquiry.

clearlabs.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Clear Dx
Description

Automated genomic solutions for oncology research and clinical applications

clearlabs.com
+2 more records
Core offering1 text field

Clear Labs builds fully automated next-generation sequencing (NGS) platforms combining liquid handling, library preparation, sequencing, and bioinformatics into a single integrated system. The company sells three main product lines—Clear Dx for oncology research, Clear Ix for infectious disease research, and Clear Safety for food safety testing—to food manufacturers, public health laboratories, clinical microbiology labs, and oncology research institutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Turnaround time reduced from 4-5 days (traditional) to 24 hours
+6 more records
Product overview1 text field

Clear Labs offers a portfolio of fully automated next-generation sequencing (NGS) platforms organized into three main product lines: Clear Dx™ for clinical oncology research, Clear Ix™ for infectious disease research, and Clear Safety™ for food safety testing. The Clear Dx™ platform serves as the core clinical product supporting oncology workflows including solid tumor sequencing, liquid biopsy, and fusion detection, with extensions into microbial surveillance and targeted NGS assays. Clear Ix™ provides automated NGS capabilities for infectious disease applications including pathogen identification, TB detection, and SARS-CoV-2 surveillance. Clear Safety™ delivers food safety pathogen detection using NGS for Listeria and Salmonella testing with environmental mapping. All platforms feature walkaway automation reducing hands-on time to under 45 minutes with single human touchpoints, integrated bioinformatics, and cloud connectivity for data management.

Product and service7 records
1Clear Dx™
CategoryAutomated NGS Platform - Oncology Research
Description

Automated next-generation sequencing (NGS) platform designed for oncology research workflows including solid tumor sequencing, liquid biopsy applications, and fusion detection assays. Automates library preparation and sequencing setup, reducing hands-on time while improving consistency and reproducibility across complex genomic assays. Targets cancer research laboratories and diagnostic companies.

2Clear Ix™
CategoryAutomated NGS Platform - Infectious Disease Research
Description

Automated NGS platform for infectious disease and microbial genomics research. Streamlines pathogen characterization and genomic surveillance workflows including targeted 16S/ITS sequencing, Mycobacterium species detection, whole genome sequencing of bacterial/fungal/viral targets, and SARS-CoV-2 sequencing from clinical specimens and wastewater. Targets public health laboratories and clinical microbiology labs.

3Clear Safety™
CategoryAutomated NGS Platform - Food Safety Testing
Description

NGS-based food safety testing platform for routine pathogen detection and surveillance. Provides Listeria and Salmonella testing with deep molecular characterization, serotyping, persistence monitoring, and environmental mapping capabilities for food safety environmental monitoring and quality assurance. Targets food manufacturers and processors.

4Clear Dx™ Microbial Surveillance WGS
CategoryNGS Assay - Microbial Surveillance
Description

Fully-automated, end-to-end whole genome sequencing (WGS) solution for bacterial and fungal isolates. Supports flexible workflow options with or without nucleic acid extraction for outbreak investigation and pathogen surveillance. Reduces turnaround time from 44-47 hours to 28 hours and achieves 99% concordance with manual methods.

5Clear Dx™ Microbial ID tNGS
CategoryNGS Assay - Microbial Identification
Description

Targeted next-generation sequencing (tNGS) assay workflow for rapid detection of multiple bacteria and/or fungi that are difficult to culture. Enables next-day identification of bacterial and fungal pathogens from sterile site specimens for clinical microbiology laboratories.

6Clear Ix™ Deeplex® Myc-TB
CategoryNGS Assay - Tuberculosis Diagnostics
Description

Automated targeted sequencing solution for rapid characterization of Mycobacterium DNA extracts from isolates or sputum, enabling quick identification of over 150 Mycobacterium species and MTB drug resistance mutations. Targets public health and clinical laboratories conducting TB diagnostics.

7Clear Dx™ FlexPro: Wastewater (SARS-CoV-2)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-14
Description

Clear Labs announced collaboration with Labcorp to develop streamlined, oncology-focused NGS workflows. The partnership extends Clear Labs' automation technology beyond infectious diseases into scalable, in-house genomic testing for oncology, marking a significant strategic expansion into clinical diagnostics.

2Pillar Biosciences
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-13
Description

Clear Labs unveiled automated workflow featuring Pillar Biosciences' SLIMamp® chemistry on the Clear Dx™ platform at AMP 2025. The workflow will be available for Pillar's oncoReveal® assays, enhancing oncology research with streamlined automation starting November 2025.

prweb.com
3The Acheson Group
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-07-31
Description

Joint webinar addressing automation of NGS and regulatory landscape for food safety testing, featuring Clear Labs' Director of Product Management and TAG's COO & EVP of Regulatory & Scientific Affairs.

clearlabs.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-12-01
Description

Clear Labs inked distribution partnership with Illumina to include short-read sequencing-by-synthesis (SBS) technology in its fully integrated platform, expanding the utility of the Clear Dx platform to other sequencing applications.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-03-25
Description

North American distribution agreement where Clear Labs implements ONT's long-read GridION sequencing technology into a fully automated, highly rapid NGS platform for food safety testing applications.

Strategic tierMinorTypeOthers
Description

Clear Labs holds AOAC certification for its Salmonella and Listeria testing methods, demonstrating compliance with international standards for food testing accuracy.

Strategic tierMinorTypeOthers
Description

Clear Labs participates in ASM Corporate Council and exhibits at ASM Microbe conferences, contributing to the microbiology professional community.

Strategic tierMinorTypeOthers
Description

Clear Labs is a sustaining member of APHL and presents at annual conferences, supporting public health laboratory innovation.

Strategic tierMinorTypeOthers
Description

Clear Labs showcases oncology solutions at AMP Annual Meeting and presents scientific posters on NGS applications.

Strategic tierMinorTypeOthers
Description

Clear Labs presents scientific posters at IAFP Annual Meeting and contributes to food safety professional community.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in in vitro diagnostics and microbial testing, with strong food pathogen detection portfolio including BioFire molecular diagnostics. Comparable as an incumbent in clinical microbiology and industrial food safety testing that Clear Labs competes with for pathogen detection market share.

TypeBroad incumbent
Description

Global molecular diagnostics and sample preparation technology provider serving food safety, clinical diagnostics, and research markets. Comparable in providing integrated sample-to-result workflows for pathogen detection and oncology testing.

TypeDirect peer
Description

Leading manufacturer of liquid handling robots, automated workstations, and laboratory automation solutions. Directly comparable as a provider of walkaway automation that Clear Labs' NGS platform competes against in lab workflow automation.

TypeBroad incumbent
Description

Dominant NGS sequencing technology provider whose SBS chemistry is integrated into Clear Labs' Clear Dx platform. Also a distribution partner. Comparable as the foundational sequencing technology Clear Labs builds upon and competes with for clinical NGS workflows.

TypeBroad incumbent
Description

Major molecular diagnostics company with Panther system and extensive women's health/infection testing menu. Comparable as a clinical diagnostics incumbent offering automated molecular testing platforms to hospital and reference lab customers.

TypeDirect peer
Description

Long-read sequencing technology provider and Clear Labs distribution partner for GridION. Directly comparable as both a technology supplier and competitor offering sequencing-based pathogen detection solutions in food safety and clinical research.

TypeBroad incumbent
Description

Major life science instrumentation company offering droplet digital PCR, food safety testing kits, and laboratory automation solutions. Comparable as an incumbent providing pathogen detection and lab workflow automation to clinical and food safety markets.

TypeBroad incumbent
Description

Global life sciences giant offering NGS instruments (Ion Torrent), qPCR, laboratory automation, and clinical diagnostics. Comparable as a broad incumbent providing end-to-end genomics workflows including instruments, reagents, and informatics across all Clear Labs' target markets.

TypeEmerging player
Description

Emerging lab automation provider offering affordable pipetting robots and automated NGS library prep workstations. Comparable as a competing next-generation lab automation platform targeting genomics workflows in research and clinical labs.

TypeDirect peer
Description

Major food safety testing provider following 3M Food Safety divestiture, offering pathogen detection kits and instruments for Listeria, Salmonella, and other foodborne pathogens. Directly comparable as the dominant incumbent in the food safety pathogen testing market that Clear Safety competes against.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors24 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clear Labs

Automated Genomics Sequencing Platformsclearlabs.com

Clear Labs is a San Carlos-based biotechnology company that builds fully automated next-generation sequencing platforms for food safety testing, infectious disease surveillance, and oncology research, serving public health laboratories, food manufacturers, and clinical microbiology laboratories.

What Clear Labs does

Clear Labs is a San Carlos, California-based biotechnology company founded in 2014 by Sasan Amini (PhD, Princeton) that builds fully automated next-generation sequencing (NGS) platforms integrating liquid handling, library preparation, sequencing, and bioinformatics into a single turnkey system. The company's technology combines short-read Illumina sequencing-by-synthesis and long-read Oxford Nanopore technologies, supported by what the company describes as the world's largest molecular food database. Its product portfolio is organized into three lines: Clear Safety for food safety pathogen testing (Listeria and Salmonella with AOAC and USDA NPIP certifications), Clear Ix for infectious disease research and microbial surveillance (including SARS-CoV-2 wastewater monitoring, Mycobacterium detection, and Deeplex Myc-TB), and Clear Dx for oncology research workflows including solid tumor sequencing, liquid biopsy, and fusion detection.

The company generates revenue through sale or lease of NGS instruments, recurring consumables (reagents and kits), service contracts, and technology licensing. Go-to-market is enterprise sales-led with distribution partnerships extending reach through Illumina and Oxford Nanopore channels. Target customers span four primary verticals: food manufacturers and processors, public health laboratories, clinical microbiology laboratories, and oncology research institutions. Notable accounts include Mayo Clinic, Cleveland Clinic, Tyson Foods, Aviagen, Labcorp, Nebraska and Florida public health laboratories, and alignment with CDC PulseNet reporting standards.

Clear Labs has raised approximately $155.5M across eight disclosed funding rounds from 2014 through January 2025, with institutional backing from Menlo Ventures, Khosla Ventures, GV, Counterpoint Global, T. Rowe Price, and strategic investment from Tyson Ventures. Regulatory milestones include FDA Emergency Use Authorization for SARS-CoV-2 (2020), AOAC certifications for both Salmonella (2018) and Listeria (2019), and USDA NPIP approval for poultry Salmonella testing (2021). The company employs 51-100 people and is actively expanding internationally into Europe and Latin America while broadening its oncology footprint through partnerships with Labcorp and Pillar Biosciences announced in November 2025.

Clear Labs firmographics

Firmographics
Name
Clear Labs
Legal name
Clear Labs, Inc.
Website
https://clearlabs.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Clear Labs is a San Carlos-based biotechnology company that builds fully automated next-generation sequencing platforms for food safety testing, infectious disease surveillance, and oncology research, serving public health laboratories, food manufacturers, and clinical microbiology laboratories.
Ownership category
akta.pro rank

Clear Labs industry classification

Industry
Product category
Automated Genomics Sequencing Platforms
NAICS
Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Laboratory Analytical Instruments (3826), Laboratory Apparatus & Furniture (3821)
akta.pro industry
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLACAMAK
Lab Analytics, Utilization Management & Operational Intelligence
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics

Keywords

  • Automated genomic sequencing
  • Food safety testing
  • Infectious disease diagnostics
  • Oncology research platforms
  • Pathogen detection

Where Clear Labs is headquartered

Location

Headquarters

HQ city
San Carlos
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Clear Labs business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. NGS Platform Sales and Service: Clear Labs generates revenue through the sale and service of its automated NGS platforms including Clear Dx, Clear Ix, and Clear Safety systems. Revenue comes from instrument sales, consumables (reagents, kits), and service contracts for maintenance and support. The company offers both purchase and lease arrangements for its platforms.
  2. Testing Services and Consumables: Ongoing revenue from consumables used with the NGS platforms for pathogen detection, serotyping, and genomic surveillance applications. Customers include food safety labs, public health laboratories, and clinical microbiology labs that run routine tests.
  3. Technology Licensing and Partnerships: Revenue derived from licensing technology to partners including Labcorp for oncology workflows and distribution agreements with Illumina and Oxford Nanopore for sequencing technology integration.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise platform sale with flexible arrangements

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Clear Labs product offering

Product offering

Core offering

Clear Labs builds fully automated next-generation sequencing (NGS) platforms combining liquid handling, library preparation, sequencing, and bioinformatics into a single integrated system. The company sells three main product lines—Clear Dx for oncology research, Clear Ix for infectious disease research, and Clear Safety for food safety testing—to food manufacturers, public health laboratories, clinical microbiology labs, and oncology research institutions.

Product overview

Clear Labs offers a portfolio of fully automated next-generation sequencing (NGS) platforms organized into three main product lines: Clear Dx™ for clinical oncology research, Clear Ix™ for infectious disease research, and Clear Safety™ for food safety testing. The Clear Dx™ platform serves as the core clinical product supporting oncology workflows including solid tumor sequencing, liquid biopsy, and fusion detection, with extensions into microbial surveillance and targeted NGS assays. Clear Ix™ provides automated NGS capabilities for infectious disease applications including pathogen identification, TB detection, and SARS-CoV-2 surveillance. Clear Safety™ delivers food safety pathogen detection using NGS for Listeria and Salmonella testing with environmental mapping. All platforms feature walkaway automation reducing hands-on time to under 45 minutes with single human touchpoints, integrated bioinformatics, and cloud connectivity for data management.

Differentiator

Problem solved

Functional benefit

Brands

  • Clear Dx: Automated genomic solutions for oncology research and clinical applications
  • Clear Ix
  • Clear Safety

Products and services

  • Clear Dx™ Automated next-generation sequencing (NGS) platform designed for oncology research workflows including solid tumor sequencing, liquid biopsy applications, and fusion detection assays. Automates library preparation and sequencing setup, reducing hands-on time while improving consistency and reproducibility across complex genomic assays. Targets cancer research laboratories and diagnostic companies.
  • Clear Ix™ Automated NGS platform for infectious disease and microbial genomics research. Streamlines pathogen characterization and genomic surveillance workflows including targeted 16S/ITS sequencing, Mycobacterium species detection, whole genome sequencing of bacterial/fungal/viral targets, and SARS-CoV-2 sequencing from clinical specimens and wastewater. Targets public health laboratories and clinical microbiology labs.
  • Clear Safety™ NGS-based food safety testing platform for routine pathogen detection and surveillance. Provides Listeria and Salmonella testing with deep molecular characterization, serotyping, persistence monitoring, and environmental mapping capabilities for food safety environmental monitoring and quality assurance. Targets food manufacturers and processors.
  • Clear Dx™ Microbial Surveillance WGS Fully-automated, end-to-end whole genome sequencing (WGS) solution for bacterial and fungal isolates. Supports flexible workflow options with or without nucleic acid extraction for outbreak investigation and pathogen surveillance. Reduces turnaround time from 44-47 hours to 28 hours and achieves 99% concordance with manual methods.
  • Clear Dx™ Microbial ID tNGS Targeted next-generation sequencing (tNGS) assay workflow for rapid detection of multiple bacteria and/or fungi that are difficult to culture. Enables next-day identification of bacterial and fungal pathogens from sterile site specimens for clinical microbiology laboratories.
  • Clear Ix™ Deeplex® Myc-TB Automated targeted sequencing solution for rapid characterization of Mycobacterium DNA extracts from isolates or sputum, enabling quick identification of over 150 Mycobacterium species and MTB drug resistance mutations. Targets public health and clinical laboratories conducting TB diagnostics.
  • Clear Dx™ FlexPro: Wastewater (SARS-CoV-2)

Quantifiable outcome

  • Turnaround time reduced from 4-5 days (traditional) to 24 hours
  • +6 more outcomes

Companies that use Clear Labs

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Clear Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature9 records

Clear Labs partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • LabcorpcoreStrategic or Co-development Partner · 14 November 2025Clear Labs announced collaboration with Labcorp to develop streamlined, oncology-focused NGS workflows. The partnership extends Clear Labs' automation technology beyond infectious diseases into scalable, in-house genomic testing for oncology, marking a significant strategic expansion into clinical diagnostics.
  • Pillar BiosciencescoreTechnology or Integration · 13 November 2025Clear Labs unveiled automated workflow featuring Pillar Biosciences' SLIMamp® chemistry on the Clear Dx™ platform at AMP 2025. The workflow will be available for Pillar's oncoReveal® assays, enhancing oncology research with streamlined automation starting November 2025.
  • The Acheson GroupminorImplementation/ SI/ Consulting Partner · 31 July 2025Joint webinar addressing automation of NGS and regulatory landscape for food safety testing, featuring Clear Labs' Director of Product Management and TAG's COO & EVP of Regulatory & Scientific Affairs.
  • IlluminacoreTechnology or Integration · 1 December 2022Clear Labs inked distribution partnership with Illumina to include short-read sequencing-by-synthesis (SBS) technology in its fully integrated platform, expanding the utility of the Clear Dx platform to other sequencing applications.
  • Oxford Nanopore TechnologiescoreTechnology or Integration · 25 March 2019North American distribution agreement where Clear Labs implements ONT's long-read GridION sequencing technology into a fully automated, highly rapid NGS platform for food safety testing applications.
  • AOAC InternationalminorOthersClear Labs holds AOAC certification for its Salmonella and Listeria testing methods, demonstrating compliance with international standards for food testing accuracy.
  • American Society for Microbiology (ASM)minorOthersClear Labs participates in ASM Corporate Council and exhibits at ASM Microbe conferences, contributing to the microbiology professional community.
  • Association of Public Health Laboratories (APHL)minorOthersClear Labs is a sustaining member of APHL and presents at annual conferences, supporting public health laboratory innovation.
  • Association for Molecular Pathology (AMP)minorOthersClear Labs showcases oncology solutions at AMP Annual Meeting and presents scientific posters on NGS applications.
  • International Association for Food Protection (IAFP)minorOthersClear Labs presents scientific posters at IAFP Annual Meeting and contributes to food safety professional community.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Clear Labs competitors and assessment

Company assessment

Broad incumbents

  • bioMérieux: Global leader in in vitro diagnostics and microbial testing, with strong food pathogen detection portfolio including BioFire molecular diagnostics. Comparable as an incumbent in clinical microbiology and industrial food safety testing that Clear Labs competes with for pathogen detection market share.
  • QIAGEN: Global molecular diagnostics and sample preparation technology provider serving food safety, clinical diagnostics, and research markets. Comparable in providing integrated sample-to-result workflows for pathogen detection and oncology testing.
  • Illumina: Dominant NGS sequencing technology provider whose SBS chemistry is integrated into Clear Labs' Clear Dx platform. Also a distribution partner. Comparable as the foundational sequencing technology Clear Labs builds upon and competes with for clinical NGS workflows.
  • Hologic: Major molecular diagnostics company with Panther system and extensive women's health/infection testing menu. Comparable as a clinical diagnostics incumbent offering automated molecular testing platforms to hospital and reference lab customers.
  • Bio-Rad Laboratories: Major life science instrumentation company offering droplet digital PCR, food safety testing kits, and laboratory automation solutions. Comparable as an incumbent providing pathogen detection and lab workflow automation to clinical and food safety markets.
  • Thermo Fisher Scientific: Global life sciences giant offering NGS instruments (Ion Torrent), qPCR, laboratory automation, and clinical diagnostics. Comparable as a broad incumbent providing end-to-end genomics workflows including instruments, reagents, and informatics across all Clear Labs' target markets.

Direct peers

  • Hamilton Company: Leading manufacturer of liquid handling robots, automated workstations, and laboratory automation solutions. Directly comparable as a provider of walkaway automation that Clear Labs' NGS platform competes against in lab workflow automation.
  • Oxford Nanopore Technologies: Long-read sequencing technology provider and Clear Labs distribution partner for GridION. Directly comparable as both a technology supplier and competitor offering sequencing-based pathogen detection solutions in food safety and clinical research.
  • Neogen (3M Food Safety): Major food safety testing provider following 3M Food Safety divestiture, offering pathogen detection kits and instruments for Listeria, Salmonella, and other foodborne pathogens. Directly comparable as the dominant incumbent in the food safety pathogen testing market that Clear Safety competes against.

Emerging players

  • Opentrons: Emerging lab automation provider offering affordable pipetting robots and automated NGS library prep workstations. Comparable as a competing next-generation lab automation platform targeting genomics workflows in research and clinical labs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

Clear Labs social profiles

Digital presence

Clear Labs compliance and trust

Trust signal

Compliance4 records

Clear Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clear Labs leadership team

Management profile

Number of profiles

Profiles8 records

Clear Labs funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clear Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clear Labs

What does Clear Labs do?

Clear Labs builds fully automated next-generation sequencing (NGS) platforms combining liquid handling, library preparation, sequencing, and bioinformatics into a single integrated system. The company sells three main product lines—Clear Dx for oncology research, Clear Ix for infectious disease research, and Clear Safety for food safety testing—to food manufacturers, public health laboratories, clinical microbiology labs, and oncology research institutions.

Is Clear Labs a public or private company?

Clear Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Clear Labs founded?

Clear Labs was founded in 2014. It employs 51 to 100 people.

Where is Clear Labs based?

Clear Labs is headquartered in San Carlos, United States, in the North America region.

How does Clear Labs make money?

Three revenue lines are on record. NGS Platform Sales and Service is the primary driver. The others are testing Services and Consumables and technology Licensing and Partnerships.

Who are Clear Labs's main competitors?

Broad incumbents on record are bioMérieux, QIAGEN, Illumina, Hologic, Bio-Rad Laboratories and Thermo Fisher Scientific. Direct peers are Hamilton Company, Oxford Nanopore Technologies and Neogen (3M Food Safety). Opentrons is listed as an emerging player.

Does Clear Labs have an API?

Yes. Clear Ix™ software offers Open API integration for genomic metadata analysis, with sequencing files and quality metrics available for download after analysis. The platform is designed to integrate with secondary and tertiary bioinformatics platforms for variant analysis, interpretation, and results reporting.

What industry is Clear Labs in?

Clear Labs's product category is Automated Genomics Sequencing Platforms. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebClear Labs Expands Collaboration with Pillar Biosciences to Automate oncoReveal® Myeloid v2 and Essential MPN Panels on the Clear Dx® PlatformClear Labs announced an expanded collaboration with Pillar Biosciences to automate Pillar's oncoReveal Myeloid v2 and Essential MPN panels on the Clear Dx platform. The automation reduces hands-on time and standardizes results, marking Clear Labs' first application of automation to hematologic malignancies. The workflows are expected to be available in early 2027.PitchBookAI can help spot ‘bad lettuce.’ That doesn’t make it a good business.Investors and venture partners say building agtech around detecting foodborne outbreaks, such as cyclosporiasis linked to lettuce, is chasing a fad rather than a sustainable business. Clear Labs CEO Sasan Amini said his AI screening service, used by CDC and FDA labs, makes up only a mid-teens share of the company's business. Investors argue food safety demand is regulatory rather than epidemiological, limiting voluntary spending.B2B SaaS BlogClear Labs Revenue 2025: $12M ARR (Bootstrapped)Clear Labs, a private genomics testing company based in the United States, reported reaching $12 million in annual recurring revenue for 2025. The company has achieved this financial milestone while remaining bootstrapped and self-funded since its founding in 2014, without raising external venture capital. As of September 2025, Clear Labs employs approximately 79 people.PrwebClear Labs Showcases Oncology NGS Automation Initiatives and Announces Collaboration with LabcorpClear Labs announced its expansion into oncology-focused next-generation sequencing workflows at the Association for Molecular Pathology Annual Meeting in Boston, marking a strategic move beyond its existing infectious disease sequencing business. The company formalized a collaboration with Labcorp to develop streamlined, end-to-end automation of PGDx kitted oncology NGS assays on the Clear Dx platform, aimed at improving laboratory efficiency, consistency, and throughput. This partnership establishes a foundation for future adoption across a broader range of genomic applications.PrwebClear Labs Unveils Automated Workflow Featuring Pillar Biosciences' SLIMamp® Technology at AMP 2025Clear Labs has announced a new automated NGS workflow featuring Pillar Biosciences' SLIMamp® chemistry on the Clear Dx™ platform, debuting at the AMP Annual Meeting in Boston. The integrated workflow enables laboratories to perform streamlined, end-to-end oncology workflows with reduced hands-on time and standardized automation. Early-access availability begins November 2025 for Pillar's oncoReveal Solid Tumor 22 Gene Research Use Only panel.TechStartupsHuman DNA in Hot Dogs: What You Need to KnowClear Labs' 2015 study of 345 hot dog products found human DNA in 2% of samples and meat in 10% of vegetarian products. The DNA is incidental from sanitation lapses, not a health risk, and regulators confirm it doesn't violate food safety standards.PrwebClear Labs Launches New Fully Automated NGS Platform for Rapid Bacterial and Fungal Detection from Sterile Site SpecimensClear Labs launched the Clear Dx™ Microbial ID tNGS assay, an automated next-generation sequencing platform designed for rapid identification of bacteria and fungi from sterile site specimens. The system delivers next-day results with minimal hands-on time by automating the entire workflow, including PCR and library preparation.AsmAutomated whole genome sequencing platform for bacterial strain typing in clinical microbiology laboratoriesA study compared the automated Clear Dx WGS platform from Clear Labs against manual whole genome sequencing methods for bacterial strain typing in clinical microbiology. The automated workflow demonstrated 99% concordance with manual results while reducing turnaround time by 16–19 hours and cutting costs by an estimated 34%–57%. These findings highlight the efficiency and cost-effectiveness of integrating automation into bacterial genomic surveillance workflows.